StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) KPIs and segments

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3011% above fair value
$957.76+5.36 (+0.56%)

Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Regeneron Pharmaceuticals · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Regeneron Pharmaceuticals: 46 chỉ số vận hành, trong đó có Dupixent (dupilumab, EYLEA HD & EYLEA Franchise (aflibercept và Libtayo (cemiplimab, lấy từ 186 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Collaboration revenue($M)
3,0012,4551,9001,9711,9681,8611,5311,6071,6601,5241,2671,370
Net product sales($M)
1,8051,6421,5351,6751,5881,6311,4162,0031,9461,9191,7611,852
EYLEA1
United States($M)
4004124735776817547361,1901,1451,2311,2021,338
Libtayo($M)2
550489438425365377285367289297264244
United States($M)
396343286285219248193251195182159155
Rest Of World($M)
15414715214014612992.611694.111510589
Other revenue($M)
31019317123919818481.9179114105117213
Inmazeb($M)2
35.601
United States($M)
37.4040.235.662.1
Rest Of World($M)
0001
Lynozyfic($M)
1916.511.20.8000
Other products($M)
0.80031.310.100000
Evkeeza1
United States($M)
55.553.345.747.342.841.230.938.132.430.424.824
Praluent1
United States($M)
81.574.766.672.267.765.856.862.752.956.17061.3
EYLEA HD1
United States($M)
699596468431393307
EYLEA HD And EYLEA1
United States($M)
1,0991,0099421,1111,1481,043
ELYEA HD And EYLEA1
United States($M)
1,0831,1111,1481,0431,4951,5371,5351,4021,461
ELYEA HD1
United States($M)
506431393307305392304200123
Dupixent (dupilumab — recorded by Sanofi) — Global Net Product Sales ($M)($M)3
6,5415,9984,8804,9404,8574,3453,6663,6983,8173,5563,0773,216
Dupixent (dupilumab — recorded by Sanofi) — U.S. Net Product Sales ($M)($M)
5,0644,5613,5583,7343,6193,2052,6292,7462,8252,6102,2182,486
Dupixent (dupilumab — recorded by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M)
1,4761,4371,3221,2061,2381,1401,036952993946859730
Dupixent (dupilumab — recorded by Sanofi) — Global Net Product Sales YoY Growth (%)(%)
35.0%38.0%33.0%34.0%27.0%22.0%19.0%15.0%23.0%27.0%24.0%31.0%
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Global Net Product Sales ($M)($M)4
1,7411,6751,6701,9001,9652,1251,9012,3832,4692,4432,2512,350
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Rest of World (ROW) Net Product Sales ($M)($M)
643667729817854978858888932908849890
EYLEA HD & EYLEA Franchise (aflibercept — U.S. by Regeneron, ROW by Bayer) — Global Net Product Sales YoY Growth (%)(%)
-11.0%-21.0%-12.0%-20.0%-20.0%-13.0%-16.0%1.0%4.0%2.0%-1.0%1.0%
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Global Net Product Sales ($M)($M)2
1,083963801819663635453395468363215123
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Rest of World (ROW) Net Product Sales ($M)($M)
38436633331223224214690.475.259.115.2
EYLEA HD / EYLEA 8 mg (aflibercept 8 mg) — Global Net Product Sales YoY Growth (%)(%)
63.0%52.0%77.0%107.0%42.0%75.0%111.0%
EYLEA (aflibercept 2 mg) — Global Net Product Sales ($M)($M)2
6587128691,0821,3021,4901,4471,9882,0012,0792,0362,227
EYLEA (aflibercept 2 mg) — Rest of World (ROW) Net Product Sales ($M)($M)
259300396505621736711798857849834890
EYLEA (aflibercept 2 mg) — Global Net Product Sales YoY Growth (%)(%)
-49.0%-52.0%-40.0%-46.0%-35.0%-28.0%-29.0%-5.0%
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Global Net Product Sales ($M)($M)2
550489438425365377285367289297264244
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Rest of World (ROW) Net Product Sales ($M)($M)
15414715214014612992.611694.111510589
Libtayo (cemiplimab — Global by Regeneron since Q3 2022) — Global Net Product Sales YoY Growth (%)(%)
51.0%30.0%54.0%16.0%27.0%27.0%8.0%50.0%24.0%42.0%45.0%44.0%
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Global Net Product Sales ($M)($M)2
261266246226216222193180191192201187
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M)
179191179154148156137118139136131126
Praluent (alirocumab — U.S. by Regeneron, ROW by Sanofi) — Global Net Product Sales YoY Growth (%)(%)
21.0%20.0%27.0%25.0%13.0%16.0%-4.0%-4.0%16.0%37.0%38.0%40.0%
Kevzara (sarilumab — recorded by Sanofi) — Global Net Product Sales ($M)($M)3
25620614515215415211613512011094.1112
Kevzara (sarilumab — recorded by Sanofi) — U.S. Net Product Sales ($M)($M)
19314310110010395.772.882.472.765.15066.2
Kevzara (sarilumab — recorded by Sanofi) — Rest of World (ROW) Net Product Sales ($M)($M)
62.962.544.35251.156.543.652.447.444.644.146
Kevzara (sarilumab — recorded by Sanofi) — Global Net Product Sales YoY Growth (%)(%)
66.0%35.0%24.0%13.0%28.0%39.0%24.0%20.0%25.0%10.0%20.0%38.0%
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — Global Net Product Sales ($M)($M)2
1916.511.20.80
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — U.S. Net Product Sales ($M)($M)
18.616.210.70.80
Lynozyfic (linvoseltamab — Global by Regeneron, launched 2025) — Rest of World (ROW) Net Product Sales ($M)($M)
0.400.300.50
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Global Net Product Sales ($M)($M)4
91.384.610612571.172.154.610392.652.844.2105
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — U.S. Net Product Sales ($M)($M)
56.25477.192.943.142.131.178.568.230.925.386.5
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Rest of World (ROW) Net Product Sales ($M)($M)
35.130.629.331.8283023.524.824.421.918.918.5
Other Regeneron-Discovered Products (Evkeeza, Inmazeb, Veopoz, ARCALYST, ZALTRAP) — Global Net Product Sales YoY Growth (%)(%)
28.0%17.0%95.0%21.0%-22.0%37.0%24.0%-2.0%135.0%31.0%24.0%232.0%
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Global Net Product Sales ($M)($M)2
1.201.101.205.60
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Rest of World (ROW) Net Product Sales ($M)($M)
1.201.101.205.60
REGEN-COV / Ronapreve (casirivimab & imdevimab — U.S. by Regeneron, ROW by Roche) [legacy FY20–FY24] — Global Net Product Sales YoY Growth (%)(%)
-100.0%-100.0%-99.0%
Total Consolidated Revenues Recorded by Regeneron ($M)($M)3
5,1164,2913,6053,8843,7543,6763,0293,7893,7213,5473,1453,434
Total Consolidated Revenues YoY Growth (%)(%)
36.0%17.0%19.0%3.0%1.0%4.0%-4.0%10.0%11.0%12.0%-1.0%1.0%
Net Product Sales Recorded by Regeneron ($M)($M)5
1,8051,6421,5351,6751,5881,6311,4162,0031,9461,9191,7611,852
Net Product Sales Recorded by Regeneron YoY Growth (%)(%)
14.0%1.0%8.0%-16.0%-18.0%-15.0%-20.0%8.0%9.0%8.0%6.0%9.0%
EYLEA HD & EYLEA Total — U.S. Net Product Sales ($M)($M)3
1,0991,0099421,0831,1111,1481,0431,4951,5371,5351,4021,461
EYLEA HD & EYLEA Total U.S. Net Product Sales YoY Growth (%)(%)
-1.0%-12.0%-10.0%-28.0%-28.0%-25.0%-26.0%2.0%3.0%2.0%-2.0%-2.0%
EYLEA HD — U.S. Net Product Sales ($M)($M)1
699596468506431393307305392304200123
EYLEA HD U.S. Net Product Sales YoY Growth (%)(%)
62.0%52.0%52.0%66.0%10.0%29.0%54.0%148.0%166.0%
EYLEA (2 mg) — U.S. Net Product Sales ($M)($M)1
4004124735776817547361,1901,1451,2311,2021,338
EYLEA (2 mg) U.S. Net Product Sales YoY Growth (%)(%)
-41.0%-45.0%-36.0%-52.0%-41.0%-39.0%-39.0%-11.0%-21.0%-18.0%-16.0%-11.0%
Libtayo — Global Net Product Sales Recorded by Regeneron ($M)($M)3
550489438425365377285367289297264244
Libtayo Global Net Product Sales YoY Growth (%)(%)
51.0%30.0%54.0%16.0%26.0%27.0%8.0%50.0%25.0%41.0%49.0%61.0%
Libtayo — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1
396343286285219248193251195182159155
Libtayo U.S. Net Product Sales YoY Growth (%)(%)
81.0%38.0%49.0%14.0%12.0%36.0%21.0%
Libtayo — Rest of World (ROW) Net Product Sales Recorded by Regeneron ($M)($M)1
15414715214014612992.611694.111510589
Libtayo ROW Net Product Sales YoY Growth (%)(%)
5.0%13.0%63.0%21.0%55.0%12.0%-11.0%
Praluent — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1
81.574.766.672.267.765.856.862.752.956.17061.3
Praluent U.S. Net Product Sales YoY Growth (%)(%)
21.0%14.0%18.0%16.0%26.0%18.0%-19.0%3.0%33.0%37.0%75.0%69.0%
Evkeeza — U.S. Net Product Sales Recorded by Regeneron ($M)($M)1
55.553.345.747.342.841.230.938.132.430.424.824
Evkeeza U.S. Net Product Sales YoY Growth (%)(%)
28.0%29.0%48.0%26.0%34.0%32.0%29.0%58.0%68.0%63.0%60.0%60.0%
Other Revenue (Royalties, BARDA Funding & Contract Manufacturing) ($M)($M)1
31019317123919818481.9179114105117213
Other Revenue YoY Growth (%)(%)
57.0%5.0%109.0%33.0%74.0%77.0%-30.0%-16.0%-17.0%51.0%1.0%66.0%
Total Collaboration Revenue (Sanofi, Bayer, Roche & Other) ($M)($M)3
3,0012,4551,9001,9711,9681,8611,5311,6071,6601,5241,2671,370
Sanofi Collaboration Revenue — Total ($M)($M)6
2,7242,1741,6051,6401,6171,4441,1831,2131,2631,146910993
Sanofi Collaboration Revenue YoY Growth (%)(%)
68.0%51.0%36.0%35.0%28.0%26.0%30.0%22.0%19.0%21.0%14.0%19.0%
Regeneron's Net Share of Profits (Losses) from Commercialization of Antibodies (Dupixent, Praluent, Kevzara) ($M)($M)5
2,5752,0331,4511,4861,4561,2821,0181,0431,088988804886
Antibody Profit-Sharing Schedule — Dupixent & Kevzara Net Product Sales Recorded by Sanofi ($M)($M)
6,7966,2045,0255,0925,0114,4973,7823,8323,9373,6663,1713,328
Antibody Profit-Sharing Schedule — Regeneron's Share of Collaboration Profits before Development Balance Reimbursement ($M)($M)
2,5752,2861,7281,7711,7241,4971,1801,1891,2631,1499261,032
Antibody Profit-Sharing Schedule — Reimbursement of Development Balance to Sanofi (Deduction from Profit Share) ($M)($M)
-253-277-285-268-215-162-146-175-161-122-146
Antibody Profit-Sharing Schedule — Regeneron's Net Profit Share as % of Dupixent & Kevzara Net Product Sales (%)(%)
38.0%33.0%29.0%29.0%29.0%27.0%28.0%27.0%25.0%
Sanofi Antibody Collaboration — Remaining Contingent Development Balance Payable by Regeneron ($M)($M)
2785959051,2001,4531,6351,8102,0132,2002,330
Sanofi Collaboration — Reimbursement for Manufacturing of Commercial Supplies ($M)($M)
149142154154162162165170175157106107
Sanofi Collaboration — Net R&D Expense Reimbursement / (Obligation) ($M)($M)
-38.4-19.4-16.7-12.6-23.5-18-15.5-11.3-7.80-9.10-18.6-17
Sanofi Collaboration — Reimbursement of Commercialization-Related (SG&A) Expenses ($M)($M)
196189184194183194159196169151140150
Sanofi Collaboration — Net Accounts Receivable Due from Sanofi ($M)($M)
2,8402,2721,7131,6111,4941,3371,1931,2161,2711,1339471,029
Bayer Collaboration Revenue — Total ($M)($M)5
267276287319345415344377391375356377
Bayer Collaboration Revenue YoY Growth (%)(%)
-23.0%-33.0%-17.0%-15.0%-12.0%11.0%-3.0%4.0%-1.0%6.0%
Regeneron's Share of Net Profits from Ex-U.S. Commercialization of EYLEA 8 mg & EYLEA ($M)($M)4
212227240270312383317349368353334345
Bayer Profit-Sharing Schedule — Ex-U.S. EYLEA 8 mg & EYLEA Net Product Sales Recorded by Bayer ($M)($M)
643667729817854978858888932908849890
Bayer Profit-Sharing Schedule — Regeneron's Share of Collaboration Profit before Bayer Development Reimbursement ($M)($M)
226242255286328400334366384369351361
Bayer Profit-Sharing Schedule — Reimbursement of Development Expenses Incurred by Bayer ($M)($M)
-14.8-15.1-15.4-15.7-16.1-16.5-16.3-17.2-16.6-16-16.6-15.3
Bayer Profit-Sharing Schedule — Regeneron's Net Profit Share as % of Ex-U.S. EYLEA Sales (%)(%)
33.0%34.0%33.0%37.0%39.0%37.0%39.0%39.0%39.0%
Bayer Collaboration — Reimbursement for Manufacturing of Ex-U.S. Commercial Supplies ($M)($M)
55.348.947.348.632.931.626.628.323.222.122.131.4
Bayer Collaboration — Net R&D Expense Reimbursement / (Obligation) ($M)($M)
-0.30-0.601-1.10-3.90-5.60-9.40-13.3-11.8-14.7-8.70-8.90
Bayer Collaboration — Net Accounts Receivable Due from Bayer ($M)($M)
235223241288363388373350377373359382
Roche Collaboration Revenue (Ronapreve / REGEN-COV Ex-U.S. Gross Profit Share) [legacy FY21–FY24] ($M)($M)
00.500.400.502.10
Total Accounts Receivable, Net ($M)($M)3
7,5796,5655,7315,7415,6875,6105,5616,2126,1075,7175,2225,667
Trade Accounts Receivable, Net ($M)($M)
4,1323,7843,5293,4583,4713,5813,7604,2784,1423,9583,7393,888
Customer Revenue Concentration — Besse Medical (Cencora) Share of Gross Product Revenue (%)(%)
4,800.0%4,500.0%4,500.0%4,900.0%5,200.0%5,100.0%5,100.0%5,100.0%5,100.0%
Customer Revenue Concentration — McKesson Corporation Share of Gross Product Revenue (%)(%)
3,000.0%3,200.0%3,000.0%3,000.0%2,400.0%2,500.0%2,400.0%2,400.0%2,400.0%
Total Research and Development (R&D) Expenses ($M)($M)4
1,7951,6321,5441,6261,4751,4221,3271,4121,2721,2001,2481,177
Direct Research and Development Expenses — Total ($M)($M)10
590539499461454454388430386364408333
Direct Clinical R&D — Dupixent (dupilumab) ($M)($M)
28.824.329.330.127.628.125.532.431.328.836.336
Direct Clinical R&D — Libtayo (cemiplimab) ($M)($M)
13.415.719.718.81818.520.818.417.920.222.623.1
Direct Clinical R&D — Fianlimab (anti-LAG-3 antibody) ($M)($M)
44.972.742.252.655.847.951.547.153.4516431.7
Direct Clinical R&D — Lynozyfic (linvoseltamab, BCMAxCD3 bispecific) ($M)($M)
64.263.973.847.932.853.631.730.125.423.163.314.4
Direct Clinical R&D — Ordspono (odronextamab, CD20xCD3 bispecific) ($M)($M)
57.949.348.646.350.142.826.235.333.834.326.129.7
Direct Clinical R&D — Itepekimab (anti-IL-33 antibody) ($M)($M)
33.823.621.820.928.134.528.328.424.224.219.316.2
Direct Clinical R&D — Pozelimab & Cemdisiran (anti-C5 / C5 siRNA) ($M)($M)
21.423.717.521.616.516.312.830.117.619.81217.6
Direct Clinical R&D — Trevogrumab (anti-GDF8 / myostatin antibody) ($M)($M)
11.516.316.717.923.615.514.36.405.107.10
Direct Clinical R&D — EYLEA HD (aflibercept 8 mg) ($M)($M)
16.521.122.630.322.328.925.121.924.3
Direct R&D — Other Clinical Product Candidates & Earlier-Stage Research Programs ($M)($M)
26321019691214178167172148132136138
Indirect Research and Development Expenses — Total ($M)($M)3
724714714683672673666679630621609604
Indirect R&D — Payroll and Benefits ($M)($M)
472460484461438449452433408423419406
Indirect R&D — Lab Supplies and Other Research and Development Costs ($M)($M)
76.371.559.365.867.564.96066.16356.555.952.7
Indirect R&D — Occupancy and Other Operating Costs ($M)($M)
176182171156166159154180159142135145
R&D — Clinical Manufacturing Costs ($M)($M)
508405364362381337310355307260275283
R&D — Reimbursement of R&D Expenses by Collaborators (Deduction) ($M)($M)
-26.5-26.2-33.6-36-32.8-42.3-37.3-51.4-51-44.6-43.8-42.4
Acquired In-Process Research and Development (IPR&D) Expense ($M)($M)
21.512710218.783.11012.313.856.223.97.1030
Non-GAAP Gross Margin on Net Product Sales (%)(%)3
86.0%87.0%86.0%85.0%86.0%86.0%85.0%86.0%89.0%89.0%89.0%
GAAP Gross Margin on Net Product Sales (%)(%)
82.0%78.0%76.0%81.0%82.0%83.0%81.0%84.0%87.0%87.0%86.0%
Non-GAAP Cost of Goods Sold (COGS) ($M)($M)3
246221209257227222217271217214196259
GAAP Cost of Goods Sold (COGS) ($M)($M)
322361373319281276266327262258240307
COGS Reconciling Item — Stock-Based Compensation Expense ($M)($M)
-28.9-26.7-33.125.1-19.9-20.9-19.526.618.318.220.925.1
COGS Reconciling Item — Intangible Asset Amortization Expense ($M)($M)
-47.1-43.8-39.436.9-33.7-32.4-28.729.126.125.123.221.9
GAAP Cost of Collaboration and Contract Manufacturing (COCM) ($M)($M)1
252216296266241255199239229222193210
Non-GAAP Cost of Collaboration and Contract Manufacturing (COCM) ($M)($M)
252216281241255199
Non-GAAP Research and Development (R&D) Expense ($M)($M)2
1,6541,5001,4081,3311,3501,2831,1861,2241,1461,0721,1221,031
GAAP Research and Development (R&D) Expense ($M)($M)
1,7951,6321,5441,6261,4751,4221,3271,4121,2721,2001,2481,177
R&D Reconciling Item — Stock-Based Compensation Expense ($M)($M)
-140-131-135140-125-139-141175124122123133
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)2
588574560691541542537681613667584622
GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)
678662648775658634633792714759689738
SG&A Reconciling Item — Stock-Based Compensation Expense ($M)($M)
-86.6-85.5-89.283.9-92-91.8-95.210383.182.686.282.6
Non-GAAP Other Income (Expense), Net ($M)($M)2
176172163185159189173181179166145117
GAAP Other Income (Expense), Net ($M)($M)
236234188164737439313-32.1314559-50.7175
Other Income Reconciling Item — (Gains) Losses on Investments in Equity Securities [through Q1 2025] ($M)($M)
-140213-135-393196-58.1
Non-GAAP Net Income ($M)($M)5
2,1501,5431,0401,2491,2871,4249281,3901,4621,3511,1161,366
GAAP Net Income ($M)($M)
1,9491,2977278451,4601,3928099181,3411,4327221,160
Total Pretax GAAP to Non-GAAP Reconciling Items ($M)($M)
246298377463-28234.1145585145-114488252
Income Tax Effect of GAAP to Non-GAAP Reconciling Items ($M)($M)
-48.8-54.3-67.5-91.464.7-2.10-25.6-113-23.432.8-93.8-45.3
Non-GAAP Effective Tax Rate (%)(%)1
15.0%15.5%13.9%17.1%13.1%8.3%11.6%9.9%10.7%10.8%6.1%2.4%
GAAP Effective Tax Rate (%)(%)
14.7%15.1%12.5%19.1%17.2%8.4%10.6%4.2%10.2%12.0%-3.0%-1.0%
Non-GAAP Diluted Net Income Per Share ($/sh)($)3
20.0714.299.4711.4411.8312.898.2212.0712.4611.569.5511.86
Non-GAAP Basic Net Income Per Share ($/sh)($)
21.1415.011012.1312.4213.558.7012.9213.5312.5010.3512.82
Shares Used in Calculating Non-GAAP Diluted EPS (M shares)
107.10108.00109.80109.10108.80110.40113.00115.10117.40116.90116.80115.20
Shares Used in Calculating Non-GAAP Basic EPS (M shares)
101.70102.80104.00102.90103.60105.10106.70107.60108.10108.10107.80106.60
Free Cash Flow (Table 3 Non-GAAP Reconciliation) ($M)($M)2
1,4835738489221,4179258161,0631,0491741,379838
Net Cash Provided by Operating Activities ($M)($M)
1,7838131,0791,1711,6191,1441,0451,2631,2913541,5131,090
Less: Capital Expenditures ($M)($M)
300240231249201219229200242181134251
Inventories, Net ($M)($M)5
2,8953,0843,1043,2013,2543,2063,1923,0873,0182,8742,7152,581
Inventories — Raw Materials ($M)($M)
548611631642710752839880857844815789
Inventories — Work in Process ($M)($M)
1,3451,5111,5251,6421,5661,5451,4701,3421,2301,1551,1081,122
Inventories — Finished Goods ($M)($M)
101142161190170144110140165154181147
Inventories — Other Inventories / Deferred Cost of Sales ($M)($M)
901821788728809764774726767721612522
Inventory Valuation Reserves Balance [legacy through FY23] ($M)($M)
706
Property, Plant and Equipment, Net ($M)($M)
5,7285,4595,2665,1205,0024,8414,6944,6004,4394,3064,2264,146
Intangible Assets, Net ($M)($M)
1,3161,3101,2871,2571,3811,3521,1671,1491,1201,1021,0591,039
Long-Term Debt (Senior Notes due 2030 & 2050) ($M)($M)1
1,9871,9871,9861,9861,9861,9851,9851,9841,9841,9841,9831,983
Finance Lease Liabilities ($M)($M)
000720720720720720720720720720
Share Repurchases — Cash Paid for Common Stock Repurchases ($M)($M)5
4001,1697946726641,0621,041973735604291289
Share Repurchases — Value of Shares Repurchased ($M)($M)
3771,1658036716631,0701,052976738601298291
Share Repurchases — Common Shares Repurchased (M shares)
0.501.701.001.101.901.500.600.600.30
Share Repurchase Program — Remaining Dollar Authorization Available ($M)($M)
2,1572,5346881,4862,1562,8143,8741,9172,8933,6311,2331,531
Treasury Stock — Carrying Value on Balance Sheet ($M)($M)1
20,94920,57519,41418,61317,94417,28516,21815,16714,19213,45612,85712,560
Treasury Stock — Shares Held in Treasury (M shares)
36.9036.4034.7033.7032.7031.6029.7028.2027.0026.4025.8025.50
Cash Dividends Declared Per Common Share (Initiated Q1 2025) ($/sh)($)
0.940.940.940.880.880.880.88
Total Stock-Based Compensation Expense ($M)($M)
256243257249237252256304225223230240
Income Tax Expense (Benefit) ($M)($M)1
33523110419930312796.340.4152196-21.3-12
Deferred Tax Assets, Net on Balance Sheet ($M)($M)
4,5364,3814,1914,0773,8473,5723,4433,3143,0152,8812,7652,575
Full-Time Employees — Global Total [annual] (employees)1
Average Headcount Disclosed in MD&A Operating Expenses Discussion [through Q1 2026 / FY25] (employees)
15,34315,30115,20715,15814,64214,17613,677
U.S. Personal Consumption Expenditures: Pharmaceutical & Other Medical Products — SAAR ($B)
3,858.703,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.40
Income Statement — Total revenues ($M)($M)13
5,1164,2913,6053,8843,7543,6763,0293,7893,7213,5473,1453,434
Total operating expenses ($M)($M)
3,0682,9972,9633,0042,7282,5962,4372,7992,5412,4782,3942,461
Research and development expense ($M)($M)
1,7951,6321,5441,6261,4751,4221,3271,4121,2721,2001,2481,177
Selling, general, and administrative expense ($M)($M)
678662648775658634633792714759689738
Income from operations ($M)($M)
2,0481,2946438801,0271,0805929901,1801,070751973
Other income (expense), net ($M)($M)
236234188164737439313-32.1314559-50.7175
Interest expense ($M)($M)
10.61112.912.219.33.608.7010.513.814.816.118.3
Income before income taxes ($M)($M)
2,2841,5288311,0441,7631,5199059581,4931,6287011,148
Income tax expense ($M)($M)
33523110419930312796.340.4152196-21.3-12
Net income ($M)($M)
1,9491,2977278451,4601,3928099181,3411,4327221,160
Net income per share — Basic ($/sh)($)
19.1612.626.9914.0913.247.5812.4013.256.70
Net income per share — Diluted ($/sh)($)
18.4512.236.7513.6212.817.2711.5412.416.27
Weighted-average basic shares outstanding (M)
101.70102.80104.00103.60105.10106.70108.10108.10107.80
Weighted-average diluted shares outstanding (M)
105.60106.00107.70107.20108.60111.20116.20115.40115.10
Balance Sheet — Total assets ($M)($M)15
44,40541,73140,86940,55940,16938,21937,54537,75937,44236,08734,37033,080
Cash and cash equivalents ($M)($M)
3,6592,4562,9633,1182,5061,9963,0902,4892,0121,9212,6022,730
Marketable securities — current ($M)($M)
5,6425,5395,7915,4875,9375,4745,2596,5247,7857,8887,9188,115
Accounts receivable, net ($M)($M)
7,5796,5655,7315,7415,6875,6105,5616,2126,1075,7175,2225,667
Inventories ($M)($M)
2,8953,0843,1043,2013,2543,2063,1923,0873,0182,8742,7152,581
Total current assets ($M)($M)
20,79518,44618,20918,02217,98116,86017,57218,66119,33419,08218,87219,479
Marketable securities — noncurrent ($M)($M)
9,5579,8289,78610,26110,28610,0589,2768,9008,4917,7226,9795,397
Property, plant, and equipment, net ($M)($M)
5,7285,4595,2665,1205,0024,8414,6944,6004,4394,3064,2264,146
Intangible assets, net ($M)($M)
1,3161,3101,2871,2571,3811,3521,1671,1491,1201,1021,0591,039
Deferred tax assets ($M)($M)
4,5364,3814,1914,0773,8473,5723,4433,3143,0152,8812,7652,575
Accounts payable ($M)($M)
1,1401,1591,027939904724706790497562671607
Total current liabilities ($M)($M)
6,2025,5315,1084,3684,4253,6673,5673,9443,6613,5093,5813,423
Long-term debt ($M)($M)
1,9871,9871,9861,9861,9861,9851,9851,9841,9841,9841,9831,983
Total liabilities ($M)($M)
10,90710,0199,4459,3029,2128,2808,1588,4068,1167,8817,3797,107
Retained earnings ($M)($M)
39,47237,62136,42435,79735,04633,68032,38431,67330,75529,41527,98227,260
Total stockholders' equity ($M)($M)
33,49931,71131,42431,25730,95829,93929,38829,35429,32628,20626,99125,973
Cash Flow Statement — Operating cash flow ($M)($M)6
1,7838131,0791,1711,6191,1441,0451,2631,2913541,5131,090
Depreciation and amortization ($M)($M)
121124123145137135127126122121114113
Stock-based compensation ($M)($M)
256243257249237252256304225223230240
Capital expenditures ($M)($M)
300240231249201219229200242181134251
Investing cash flow ($M)($M)
-288-92.7-429220-403-1,094648351-574-557-1,687-66.2
Financing cash flow ($M)($M)
-290-1,225-802-780-718-1,128-1,089-1,136-634-47847.1-446
Repurchases of common stock ($M)($M)
4001,1697946726641,0621,041973735604291289

20 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Regeneron Pharmaceuticals, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026; Q3 2026 ended September 30, 2026). Regeneron manages its business as a single global biopharmaceutical operating segment (Note 16), so operational performance is tracked through two distinct commercial lenses: (1) Global Net Product Sales of Regeneron-Discovered Products across U.S. and Rest of World (Table 5 — whether recorded by Regeneron or by collaboration partners Sanofi, Bayer, and Roche) and (2) Regeneron-Recorded Consolidated Revenues, Collaboration Profit-Sharing Schedules (Table 4), and Direct R&D Spend by Clinical Program.
  • Core commercial, collaboration & R&D KPIs (Groups 1–6) cover: (1) Global Net Product Sales of Regeneron-Discovered Products (Table 5: Dupixent $4,860.8M in Q3 2026 / $17,774.4M in FY25, +26% in FY25; EYLEA HD & EYLEA Franchise $1,908.7M in Q3 2026 / $8,303.6M in FY25 across EYLEA HD $661.7M and EYLEA $1,247.0M in Q3 2026; Libtayo $448.6M in Q3 2026 / $1,447.6M in FY25; Praluent $201.9M in Q3 2026 / $807.7M in FY25; Kevzara $156.9M in Q3 2026 / $596.3M in FY25; Lynozyfic $35.0M in Q3 2026; and Other Products $58.0M in Q3 2026 / $241.7M in FY25, plus legacy REGEN-COV, ARCALYST, and ZALTRAP); (2) Regeneron-Recorded Consolidated Revenues ($3,754.2M in Q3 2026 / $14,342.8M in FY25: Net Product Sales $2,299.1M in Q3 2026 / $8,522.4M in FY25, Collaboration Revenue $1,394.7M in Q3 2026 / $5,376.4M in FY25, and Other Revenue $60.4M in Q3 2026 / $444.0M in FY25); (3) Sanofi & Bayer Collaboration Revenue (Table 4) and Profit-Sharing Schedules (Sanofi Antibody Profit Share $1,517.8M in Q3 2026 / $5,263.5M in FY25, 31% of partner sales in Q3 2026 after development balance was fully reimbursed in Q2 2026; Bayer Ex-U.S. EYLEA Profit Share $328.9M in Q3 2026 / $1,439.8M in FY25, 37% of $893.4M ex-U.S. sales in Q3 2026); (4) Gross-to-Net (GTN) Sales Deductions Reserve Rollforward ($1,806.4M ending balance, $7,328.9M provisions, and $7,007.8M payments/credits in FY25 across Rebates/Chargebacks/Discounts, Distribution Fees, and Other Deductions) and Specialty Distributor Concentration (Besse Medical / Cencora 48% and McKesson 30% of gross product revenue in Q3 2026; 91% of trade AR at FY25); (5) R&D Expenses ($1,468.2M in Q3 2026 / $5,738.3M in FY25: Direct R&D $703.2M in Q3 2026 / $2,824.2M in FY25 disaggregated across Lynozyfic, Ordspono, Fianlimab, Itepekimab, Dupixent, Libtayo, Pozelimab, Trevogrumab, EYLEA HD, and Other Candidates; Indirect R&D $471.3M in Q3 2026; Clinical Manufacturing $328.7M in Q3 2026; and Collaborator Reimbursements -$35.0M in Q3 2026), Acquired IPR&D ($199.1M in Q3 2026), and Science/Pipeline KPIs (13 approved medicines, ~40 clinical candidates, >2.5M human exomes sequenced by Regeneron Genetics Center); and (6) GAAP vs. Non-GAAP Reconciliations & Free Cash Flow (Table 3: 84.0% Non-GAAP / 81.2% GAAP Gross Margin on Net Product Sales, $1,226.4M Non-GAAP Net Income, $11.42 Non-GAAP Diluted EPS, and $1,073.8M Free Cash Flow in Q3 2026).
  • Groups 7–9 cover: (7) Manufacturing Inventories by Stage ($3,477.1M net at Q3 2026: Raw Materials $727.4M, WIP $2,021.1M, Finished Goods $644.6M, Deferred Cost of Sales $84.0M), Bioreactor Cell Culture Capacity (160,000 liters in Rensselaer NY and 150,000 liters in Limerick Ireland in FY25), Facility Space (2.11M sq ft in Tarrytown NY, 2.75M sq ft in Rensselaer NY, and 818,700 sq ft in Limerick Ireland in FY25), PP&E by Category ($5,112.1M net at Q3 2026), and Intangible Assets ($914.3M net at Q3 2026 with 5-year estimated amortization schedule); (8) Senior Notes Debt ($1,986.2M at Q3 2026), Finance & Operating Leases, Capital Return ($651.2M share repurchases / 0.89M shares in Q3 2026; $1,588.8M remaining buyback authorization; $0.94/share quarterly dividend declared in Q3 2026), Stock-Based Compensation ($280.1M in Q3 2026 / $1,069.9M in FY25), and Income Taxes (DTA breakdown $4,193.5M net at Q3 2026 and UTB rollforward $878.8M at FY25); and (9) Global Workforce (15,172 full-time employees at FY25: 13,221 U.S., 1,622 Ireland, 329 Other International; 7,448 IOPS manufacturing, 3,275 Research & Preclinical, 2,265 Clinical & Regulatory), Diversity & Turnover (87% engagement, 7.6% total turnover, 51.0% women globally, 41.2% POC in U.S. at FY24), CEO Pay Ratio (35:1 / $189,031 median employee compensation in FY25), Workplace Safety (0.61 TRIR / 0.30 LTIR / 0 fatalities in FY24), STEM & Community Investment (1,452,469 students supported with a STEM experience and $461.4M in-kind donations in FY24), and Environmental Sustainability (Scope 1, 2 & 3 GHG emissions, electricity, renewable energy, water & waste).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-11-04.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Regeneron-Recorded Consolidated Revenues, Net Product Sales by Brand & Revenue Streams

Sanofi, Bayer & Roche Collaboration Revenue Breakdown & Profit-Sharing Schedules (Table 4 & Note 3)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Regeneron Pharmaceuticals

See a number that looks wrong?